Cosunter(SZ:300436) Xin Lang Cai Jing·2026-01-15 06:37Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5% to 86.62 yuan per share, with a trading volume of 617 million yuan and a turnover rate of 5.11%, resulting in a total market capitalization of 13.796 billion yuan [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company's main business involves the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund holds a position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 3.2292 million yuan [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a latest scale of 16.977 billion yuan. Year-to-date returns are 9.05%, ranking 1139 out of 8840 in its category, while the one-year return is 27.73%, ranking 4489 out of 8094 [2]